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Background: Apoptosis is an early event involved in cardiomyopathy associated with diabetes mellitus. Toll-like
receptor (TLR) signaling triggers cell apoptosis through multiple mechanisms. Up-regulation of TLR4 expression has
been shown in diabetic mice. This study aimed to delineate the role of TLR4 in myocardial apoptosis, and to block
this process through gene silencing of TLR4 in the myocardia of diabetic mice.
Methods: Diabetes was induced in C57/BL6 mice by the injection of streptozotocin. Diabetic mice were treated
with 50 μg of TLR4 siRNA or scrambled siRNA as control. Myocardial apoptosis was determined by TUNEL assay.
Results: After 7 days of hyperglycemia, the level of TLR4 mRNA in myocardial tissue was significantly elevated.
Treatment of TLR4 siRNA knocked down gene expression as well as diminished its elevation in diabetic mice.
Apoptosis was evident in cardiac tissues of diabetic mice as detected by a TUNEL assay. In contrast, treatment with
TLR4 siRNA minimized apoptosis in myocardial tissues. Mechanistically, caspase-3 activation was significantly
inhibited in mice that were treated with TLR4 siRNA, but not in mice treated with control siRNA. Additionally, gene
silencing of TLR4 resulted in suppression of apoptotic cascades, such as Fas and caspase-3 gene expression. TLR4
deficiency resulted in inhibition of reactive oxygen species (ROS) production and NADPH oxidase activity,
suggesting suppression of hyperglycemia-induced apoptosis by TLR4 is associated with attenuation of oxidative
stress to the cardiomyocytes.
Conclusions: In summary, we present novel evidence that TLR4 plays a critical role in cardiac apoptosis. This is the
first demonstration of the prevention of cardiac apoptosis in diabetic mice through silencing of the TLR4 gene.
Introduction
Hyperglycemia is the underlying abnormality character-
izing the diabetic condition. Chronic hyperglycemia
introduces a plethora of complications such as cardio-
vascular disease, which is the most frequent cause of
death in the diabetic population [1]. Diabetic patients
have a poorer prognosis post-myocardial infarction as
well as an increased risk of subsequent heart failure
[2,3]. Studies have shown hyperglycemic patients hospi-
talized with acute coronary syndromes also have higher
mortality rates [4]. A key pathological consequence of
sustained hyperglycemia is the induction of cardiomyo-
cyte apoptosis reported in both diabetic patients and
animal models of diabetes [5]. Cardiomyocyte apoptosis
causes a loss of contractile units which reduces organ
function and provokes cardiac remodeling, which is
associated with hypertrophy of viable cardiomyocytes
[5-8]. As such, should myocardial apoptosis be inhibited,
one would expect to prevent or slow the development of
heart failure. Yet, the means by which hyperglycemia
induces apoptosis in cardiomyocytes have not been fully
understood.
Toll-like receptor 4 (TLR4) is a key proximal signaling
receptor responsible for initiating the innate immune
response. TLR4 recognizes pathogen-associated molecular
patterns and plays a vital role in myocardial dysfunction
during bacterial sepsis [9] and pressure overload-induced
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any medium, provided the original work is properly cited.cardiac hypertrophy. TLR4 expression is elevated in failing
and ischemic human hearts as well as in animal models of
myocardial ischemia [10,11]. In addition, recent studies
suggest TLR4 may trigger apoptosis of cardiomyocytes in
conditions of cardiac inflammation and oxidative stress
[12]. Studies have also shown that TLR4 is increased in
diabetic mice, however, the role of TLR4 in hyperglyce-
mia-induced myocardial apoptosis has not been eluci-
dated. In this study, we initially investigated the role of
TLR4 on apoptosis in cardiomyocytes under hyperglyce-
mic conditions. Subsequently, we explored the interven-
tion of apoptosis in cardiomyocytes through RNA
interference (RNAi) using small interfering RNA (siRNA)
specific to TLR4 gene. We found that TLR4 was up-regu-
lated in the myocardia of STZ-treated diabetic mice (STZ
mice), which displayed increased expression of apoptotic
genes such as Fas and caspase-3. Treatment with TLR4
siRNA attenuated apoptosis as well suppressed ROS pro-
duction and NADPH oxidase activity.
Materials and methods
Animals
C57/BL6 mice were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA). All mice were male
and 6-8 weeks old. All experimental procedures were
approved by the Animal Use Sub-committee at the Uni-
versity of Western Ontario, Canada, in accordance with
the Guide for the Care and Use on Animals Committee
Guidelines.
Hyperglycemic mouse model
Adult male mice (6-8 weeks old) were intraperitoneally
i n j e c t e dw i t has i n g l ed o s eo fs t r e p t o z o t o c i n( S T Z )a t
150 mg/kg body weight, dissolved in 10 mM sodium
citrate buffer (pH 4.5). On day 3 after STZ treatment,
whole blood was obtained from the mouse tail vein and
random glucose levels were measured using the One-
Touch Ultra 2 blood glucose monitoring system (Life-
Scan, Mountainview, CA). For the present study,
hyperglycemia is defined as a blood glucose measure-
ment of 20 mM or higher. Citrate buffer-treated mice
were used as a normoglycemic control (blood glucose
<12 mM).
siRNA expression vectors
Three target sequences of TLR4 gene were selected. The
oligonucleotides containing sequences specific for TLR4
(5’-GATCCCGTATTAGGAACTACCTCTATGCTTGA-
TATC CGGCATAGAGGTAGTTCCTAATATTTTTTC-











TGGCGAATGG-3’) were synthesized and annealed.
A TLR4-siRNA expression vector that expresses hairpin
shRNA under the control of the mouse U6 promoter was
constructed. A pair of annealed DNA oligonucleotides
were inserted into a pRNAT-U6.1/Neo shRNA expression
vector that had been digested with BamHI and HindIII
(Genescript, Piscataway, NJ, USA). The plasmid was
suspended in water and stored at -80°C until use.
Treatment of TLR4 siRNA
TLR4 siRNA or scrambled siRNA (50 μg) was mixed
with 40 μl of transfection reagent NANOPARTICLE
(Altogen Biosystems, Las Vegas, NV, USA) with total
volume of 500 μl of 5% glucose (W/V), as per the man-
ufacturer’s instruction. The siRNA mixture was intrave-
nously injected into the C57/BL6 mouse via the tail
vein.
Real-time PCR
T o t a lR N Aw a si s o l a t e df r o mh e a r tt i s s u e su s i n gT r i z o l
reagent (Invitrogen) according to the manufacturer’s
protocol. The RNA was subsequently reverse-tran-
scribed using an oligo-(dT) primer and reverse tran-
scriptase (Invitrogen). Primers used for the amplification
of murine TLR4, Fas, caspase-3 and an internal loading
control, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were respectively, as follows: TLR4, sense 5’-
CACTGTTCTTCTCCTGCCTGAC-3’ (forward), and 5’-
CCTGGGGAAAAACTCT GGATAG-3’ (reverse); Fas,
5’-CAGAAATCGCCTATGGTTGTTG-3’ (forward), and
5’-GCT CAGCTGTGTCTTGGATGC-3’ (reverse); cas-
pase-3, 5’-TGACCATGGAGAACAACAAA ACCT-3’
(forward), and 5’-TCCGTACCAGAGCGAGATGACA-3’
(reverse); and GAPDH, 5’-TGATGACATCAAGAA
GGTGGTGAA-3’ (forward) and 5’-TGGGATG-
GAAATTGT GAGGGAGAT-3’ (reverse).
Real-time PCR reactions were performed using SYBR
Green PCR Master mix (Stratagene) and 80 nM of
gene-specific forward and reverse primers as described
above. The PCR reaction conditions were 95°C for
10 min, 95°C for 30 sec, 58°C for one min and 72°C for
30 sec (40 cycles). Amplification was performed accord-
ing to the manufacturer’s cycling protocol and done in
triplicate. Gene expression was calculated as 2
-ΔΔ(Ct)
[13], where Ct is cycle threshold, ΔΔ(Ct) = sample 1Δ
(Ct) -sample 2Δ(Ct); Δ(Ct) = GAPDH (Ct) - testing
gene (Ct). Data was analyzed using MX4000
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In situ detection of apoptotic cells
Apoptosis in heart tissue was detected using the Apop-
Tag in situ apoptosis detection kit (Qbiogene, Illkirch,
France), as specified by the manufacturer. Briefly, paraf-
fin embedded sections were deparaffinized and
pre-treated with proteinase K (20 μg/ml) for 15 min.
Equilibration buffer was added directly onto the speci-
men, after which terminal deoxynucleotidyl transferase
(TdT) enzyme in reaction buffer was added for 1 h at 37°
C. Sections were washed in Stop/Wash buffer for 10 min.
After incubating with anti-digoxigenin peroxidase conju-
gate for 30 min, the peroxidase substrate was added to
develop color. The samples were washed with PBS and
observed under a microscope in a blinded fashion, and
the proportion of cardiac cells undergoing apoptosis was
calculated.
Caspase-3 Activity
Caspase-3 activity in myocardial tissues was measured
by using a caspase-3 fluorescent assay kit (BIOMOL
Research Laboratory), as described previously [14].
Briefly, hearts from diabetic mice were homogenized,
and protein concentration was determined using the
Bradford method. Samples in duplicates were incubated
with caspase-3 substrate Ac-DEVD-AMC or Ac-DEVD-
AMC plus inhibitor AC-DEVD-CHO at 37°C for 2 h
before measurements were made by a fluorescent spec-
trophotometer (excitation at 380 nm, emission at 405
nm). Signals from inhibitor-treated samples served as
background.
NADPH oxidase activity assay
NADPH oxidase activity was assessed in cell lysates by
lucigenin-enhanced chemiluminescence (20 μgo fp r o -
tein, 100 μM NADPH, 5 μM lucigenin) with a multilabel
counter (Victor3 Wallac), as described previously [15].
Intracellular ROS measurement
The formation of ROS was measured using the ROS-
sensitive dye, 2,7-dichlorodihydro-fluorescein diacetate
(DCF-DA, Invitrogen), as an indicator. The assay was
performed on freshly dissected heart tissues. Samples
(50 μg proteins) were incubated with 10 μlo fD C F - D A
(10 μM) for 3 h at 37°C. The fluorescent product
formed was quantified by spectrofluorometer at the 485/
525 nm. Changes in fluorescence were expressed as an
arbitrary unit.
Statistical analysis
Data were expressed as the mean ± SD. Differences
between two groups were compared by unpaired
Student’s t-test. For multi-group comparison, data were
compared using a one-way analysis of variance
(ANOVA) followed by the Newman-Keuls test analysis.
Differences for the value of p < 0.05 were considered
significant.
Results
1. Up-regulation of TLR4 and apoptosis in myocardial
tissue of STZ mice
Although TLRs are reportedly up-regulated in cardio-
myocytes of diabetic patients [11], it is unclear whether
TLRs play a role in the promotion of diabetes in the
initial stages of disease or if their up-regulation is a con-
sequence of stimulation from hyperglycemia. To clarify
this, we measured TLR4 levels in mice in the early stages
of diabetes. After treatment with STZ, C57/BL6 mice
developed diabetes as evidenced by hyperglycemia (data
not shown). Significantly increased TLR4 was detected in
the myocardial tissue of STZ-mice as early as 3 days after
the appearance of hyperglycemia (Figure 1A).
We and others have previously demonstrated that
hyperglycemia is capable of inducing apoptosis in cardio-
myocytes [16-18]. Apoptosis is one of the earliest indica-
tors of cardiomyopathy in the diabetic heart and
accordingly, we measured apoptosis in STZ-treated mice.
Seven days after STZ treatment, substantial apoptosis was
detected in myocardial tissue (Figure 1B). Additionally,
Fas expression was significantly increased in STZ-treated
mice compared to control littermates (Figure 1D).
2. Prevention of hyperglycemia-induced apoptosis in
myocardial tissue by gene silencing of TLR4
Accumulating evidence suggests that activation of the
TLR4 pathway is associated with myocardial apoptosis
[12]. We explored whether knockdown of TLR4 may
suppress apoptosis of cardiomyocytes in STZ-mice. First,
we validated in vivo gene silencing of TLR4 siRNA in
myocardial tissue. After infusion of TLR4 siRNA, the
TLR4 mRNA level was decreased by 75%, as comparing
with the mice treated with scrambled control siRNA
(Figure 2A), indicative of successful knockdown in the heart
in vivo. Treatment with TLR4 siRNA did not affect the level
of blood glucose in diabetic mice (Data not shown).
Next, we examined whether gene knockdown of TLR4
has a therapeutic effect on the prevention of myocardial
apoptosis in diabetic mice. As shown in Figure 2B,
apoptosis, as detected by the TUNEL assay, was remark-
ably attenuated in mice treated with TLR4 siRNA com-
pared with scrambled siRNA.
3. Inhibition of caspase-3 in myocardia after gene
silencing of TLR4
To further confirm the Fas-FasL pathway is involved in
apoptosis of cardiomyocytes, we measured the expression
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of TLR4 siRNA resulted in the suppression of Fas expres-
sion (Figure 3A).
To understand the involvement of pro-apoptotic cas-
pases, we determined caspase-3 levels in myocardial tis-
sue. Sham-treated control mice only expressed low level
of caspase-3 while in heart tissue of STZ-treated mice,
hyperglycemia was shown to up-regulate caspase-3
expression dramatically (Figure 3B). Treatment of control
siRNA did not alter the level of caspase-3; however, treat-
ment of TLR4 siRNA effectively reversed up-regulation
of caspase-3 (Figure 3B).
To confirm caspase-3 gene suppression influences its
biological function in the apoptotic pathway, we measured
caspase-3 activity in the myocardial tissue. Caspase-3 acti-
vation was remarkably inhibited in mice treated with
TLR4 siRNA but not in mice treated with scrambled
siRNA or non-treated diabetic mice (Figure 3C).
4. Attenuation of ROS production in myocardia after gene
silencing of TLR4
It has been demonstrated that hyperglycemia may sti-
mulate the production of reactive oxygen species (ROS)
which in turn induces apoptosis in the diabetic heart
[17,19]. We measured ROS levels in the myocardia of
STZ-treated mice in order to examine the contribution
of ROS production to apoptosis and found that ROS
production was increased in mice with hyperglycemia
(Figure 4). While the treatment of scrambled siRNA did
not change the production of ROS in STZ mice, treat-
ment of TLR4 siRNA resulted in significant decrease in
R O Sp r o d u c t i o ni nt h ed i a b e t i ch e a r t( F i g u r e4 ) .
Figure 1 Up-regulation of TLR4 and increased apoptosis in the hearts of STZ mice. (A) TLR4 expression in the hearts of STZ mice. Injection
of STZ induced Type I diabetes as described in Materials and Methods. Control mice were injected with the same volume of sodium citrate
buffer (Sham). On day 7 after STZ treatment, the hearts from diabetic mice (n = 6) and sham mice (n = 6) were retrieved. Total mRNA was
extracted and used to detect the TLR4 transcripts by qPCR. (B) Determination of in situ apoptotic cells in myocardia. Apoptosis in sham-treated
mice and STZ-treated diabetic mice was detected by TUNEL assay. Representative photomicrographs of TUNEL staining in cardiomyocytes are
shown in yellow-blown signal (arrows) from (a) sham treated mice (n = 6) or (b) STZ-treated diabetic mice (n = 6). (C) Quantification of TUNEL
positive cardiomyocytes. (D) Fas expression in the hearts of STZ mice. Diabetes was induced by STZ injection as described in Materials and
Methods. On day 7 after STZ treatment, the hearts from diabetic mice (n = 6) and sham mice (n = 6) were retrieved. Total mRNA was extracted
and used to detect the Fas transcripts by qPCR. Mean ± SD are shown in A, C and D, and are representative of 3 experiments; (*) Statistical
significance when compared with sham treated mice and STZ-treated diabetic mice was denoted at p < 0.05.
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gene silencing of TLR4. (A) Suppression of TLR4 expression in the
heart of STZ mice treated with TLR4 siRNA. Diabetes was induced
by STZ injection as described in Materials and Methods. On day -1
(the day before STZ treatment), mice were intravenously injected
with 5 μg of TLR4 siRNA or scrambled control siRNA, along with
NANOPARTICLE. On day 7 after STZ treatment, the hearts from the
mice treated with TLR4 siRNA (n = 6) or scrambled siRNA (n = 6)
were retrieved. Total mRNA was extracted and used to detect the
TLR4 transcripts by qPCR. The relative quantity of TLR4 mRNA was
expressed as mean ± SD. (*) Statistical significance when compared
with scrambled siRNA treated mice was denoted as p < 0.05. (B)
Attenuation of apoptotic cells in cardiomyocyte by TLR4 siRNA.
Apoptosis in the diabetic mice treated with control siRNA (n = 6)
and TLR4 siRNA (n = 6) was detected by TUNEL assay.
Representatives of TUNEL staining in cardiomyocytes were shown in
yellow-blown signal (arrows) from the mice treated with scrambled
siRNA (a) or TLR4 siRNA (b). (C) Quantification of TUNEL positive
cardiomyocytes. Data shown are representative of 3 experiments.
Figure 3 Inhibition of caspase-3 after gene silencing of TLR4.
(A) Suppression of Fas expression in the hearts of STZ mice treated
with TLR4 siRNA. Diabetes was induced by STZ injection as
described in Materials and Methods. Diabetic mice were treated
with TLR4 siRNA (n = 6) and scrambled control siRNA (n = 6) as
described in Figure 2. On day 7 after STZ treatment, the hearts from
mice treated with TLR4 siRNA or scrambled siRNA were retrieved.
Total mRNA was extracted and used to detect Fas transcripts by
qPCR. (B) Suppression of caspase-3 expression in the heart of STZ
mice treated with TLR4 siRNA. Diabetic mice were treated with TLR4
siRNA (n = 6) and scrambled control siRNA (n = 6) as described
above. The expression of caspase-3 transcripts was detected by
qPCR. (C) Inhibition of caspase-3 activity in the heart of STZ mice
treated with TLR4 siRNA. Diabetic mice were treated with TLR4
siRNA (n = 6) and scrambled control siRNA (n = 6) as described
above. On day 7 after STZ treatment, the hearts from the mice
treated with TLR4 siRNA or scrambled siRNA were retrieved, the
protein was prepared and the caspase-3 activity was determined as
described in Methods and Materials. Relative quantity of TLR4 mRNA
and caspase-3 activity was expressed as mean ± SD. (*) Statistical
significance when compared with scrambled siRNA treated mice
was denoted as p < 0.05. Data shown are representative of 3
experiments.
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TLR4-silenced STZ mice
It has been recently reported that myocardial NADPH
oxidase activity is up-regulated in diabetes [17,20]. Addi-
tionally, accumulating evidence suggests that hyperglyce-
mia activates NADPH oxidase in cardiomyocytes [21].
Our previous study showed that NADPH oxidase con-
tributed to hyperglycemia-induced apoptosis [17]. To
explore the role of NADPH in TLR-induced myocardial
apoptosis, we measured NADPH oxidase activity. As
shown in Figure 5, NADPH oxidase activity in STZ-
mice was significantly increased. Treatment with TLR4
siRNA suppressed up-regulation of NADPH oxidase
activity (Figure 5).
Discussion
Diabetic cardiomyopathy is defined as ventricular dys-
function independent of hypertension and coronary
artery disease [22]. Apoptotic cell death is increased in
the diabetic heart of patients and animal models [6,23]
and promotes cardiomyopathy [6]. The continuous loss
of cardiomyocytes triggers myocyte hypertrophy and
fibrosis, two general hallmarks of diabetic cardiomyopa-
thy [7]. while the mechanism of hyperglycemia-induced
apoptosis is poorly understood, cell death by apoptosis
is reportedly the predominant damage in diabetic cardi-
omyopathy [6]. Moreover, diabetes increases cardiac
apoptosis in animals and patients [6,7,23]. TLRs play a
vital role in host defense but have also been described
as a promoter of apoptosis in myocardial ischemia and
dysfunction studies. Of the 10 TLRs identified in
humans, as least two, TLR2 and TLR4, exist abundantly
in the heart [24]. However, the role of TLR4 in enhan-
cing apoptosis of cardiomyocytes induced by hyperglyce-
mia has not been characterized. In this study, we
demonstrate that hyperglycemia can trigger cell death
pathways in myocardial tissues. For instance, we
observed elevations in the apoptotic gene Fas as well as
increased activation of apoptotic caspases, such as cas-
pase-3 in diabetic hearts. In addition, we demonstrate
that TLR4 is significantly increased in the myocardia of
STZ-treated mice. The apoptosis of cardiomyocytes in a
high glucose environment can be attenuated by knock-
down of the TLR4 gene. Furthermore, apoptosis is asso-
ciated with increased ROS production and up-regulation
of NADPH oxidase activity in diabetic hearts.
TLRs recognize specific structures of microorganisms
(pathogen-associated molecular patterns or PAMPs), as
well as injury-induced host-derived (“self”)s t r u c t u r e s
(damage-associated molecular patterns, or DAMPs) [25].
Upon recognition of PAMPs and DAMPs through direct
interaction and signal transduction, TLRs activate var-
ious intracellular signaling adaptors. The signaling of
TLRs occurs in the cytoplasmic portion of TLR, which
shows great similarity to that of the IL-1 receptor family
and is termed Toll/IL-1 (TIL) domain. All TLRs possess
a cytoplasmic toll IL-1 receptor (TIR) domain, and
most activated signaling cascades occur through two
pathways: MyD88/NF-kB [26] and TRIF/IRF-3 [27].
Most TLRs utilize the MyD88/NF-kB pathway that is
Figure 4 Inhibition of ROS production in TLR4-silenced STZ
mice. Diabetes was induced by STZ injection as described in
Materials and Methods. Diabetic mice were treated with TLR4 siRNA
and scrambled control siRNA as described in Figure 2. On day 7
after STZ treatment, the hearts from mice treated with TLR4 siRNA
(n = 6) or scrambled siRNA (n = 6) were retrieved, the protein was
prepared and the ROS production was determined as described in
Methods and Materials. Data are representative of 3 repeated
experiments, and are shown as mean ± SD. (*) Statistical
significance when compared with scrambled siRNA treated mice
was denoted as p < 0.05.
Figure 5 Suppression of NADPH oxidase activity in TLR4-
silenced STZ mice. Diabetes was induced by STZ injection as
described in Materials and Methods. Diabetic mice were treated
with TLR4 siRNA and scrambled control siRNA as described in
Figure 2. On day 7 after STZ treatment, the hearts from mice
treated with TLR4 siRNA (n = 6) or scrambled siRNA (n = 6) were
retrieved, the protein was prepared and the NADPH oxidase activity
was determined as described in Methods and Materials. Data are
representative of 3 repeated experiments, and are shown as mean
± SD. (*) Statistical significance when compared with scrambled
siRNA treated mice was denoted as p < 0.05.
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as TNF-a and IL-1. A few TLRs (eg., TLR3 and TLR4)
can activate alternative TRIF/IRF-3, which results in the
induction of type I interferons (IFNs) [28]. Therefore, in
terms of apoptosis, activation of TLRs in the myocardia
may initiate either pro-apoptotic or anti-apoptotic
mechanisms [24,29].
Activation of TLR4 may trigger expression of cell survi-
val and inflammatory genes via NF-B-dependent mechan-
isms. Sustained lipopolysaccharide (LPS, the ligand of
TLR4) treatment in rat hearts initiated pro-apoptotic and
survival pathways. In the same study, cardiomyocyte apop-
tosis was minor after LPS treatment [30]. Interestingly,
this modest level of apoptosis cannot be responsible for
LPS-induced cardiomyocyte dysfunction and thus, the
importance of this observation is difficult to ascertain.
Furthermore, a recent study indicated that apoptosis
resulting from myocardial ischemia-reperfusion injury was
decreased upon in vivo administration of LPS [31]. After
LPS administration, apoptosis did not occur except in
cases where endogenous survival protein synthesis was
blocked [32], thus providing further indication of parallel
survival pathways in endothelial and similar cell types. It is
likely that TLR4 and MyD88 cooperatively mediate the
anti-apoptotic effect seen in cardiomyocytes after LPS
administration [33]. In this study, we demonstrated an
up-regulation of TLR4-induced apoptosis in diabetic
hearts.
Diabetic hearts generally have ROS levels that exceed
normal amounts and likely contribute to cardiomyopa-
thy. ROS production may be enhanced by hyperglyce-
mia in cardiomyocytes [19,23]. Treatment with
antioxidants can protect cardiomyocytes from apoptosis
in high glucose conditions and as such ROS are thought
to play a key role in cardiomyocyte apoptosis in diabetes
[6,23]. The pathways culminating in accelerated ROS
production and the influence of hyperglycemia on said
pathways require further study, however, multiple
sources of ROS have been proposed including NADPH
oxidase. NADPH oxidase activity, an important factor in
the maintenance of the myocardial redox state, is ele-
vated in diabetes [17,20] and can also be over-activated
by exposure to high glucose [21]. In the present study,
ROS production and NADPH oxidase activity are signif-
icantly increased in diabetic mice yet both are sup-
pressed by the knockdown of TLR4 siRNA. Taken
together, our data suggests hyperglycemia in diabetic
mice may first up-regulate NADPH oxidase, which sub-
sequently increases ROS products which are recognized as
harmful by TLR4. In support of this view, our previous
study has shown that activation of TLR4 induces NADPH
oxidase activation and ROS production in cardiomyocytes
[15]. The activation of TLR4 and it’s down-stream signal-
ing pathways lead to up-regulation of TNF and IFN [34],
which stimulate apoptotic caspase signaling and result in
the apoptosis of cardiomyocytes.
Finally, we explored the therapeutic intervention of
apoptosis using siRNA. Specific silencing of genes with
siRNA is an advanced method of RNA interference [35]
that is more potent and specific in the knockdown of
gene expression than conventional blocking methods
[36,37]. In this study, we used siRNA to knock down
TLR4 gene and showed that the use of TLR4 siRNA can
prevent myocardial apoptosis in STZ mice, thus high-
lighting the potential clinical use of siRNA-based therapy.
Conclusion
In summary, this study defined the role of TLR4 in hyper-
glycemia-induced apoptosis in STZ mice. Treatment with
TLR4 siRNA prevented hyperglycemia-induced apoptosis,
highlighting a novel RNAi-based therapy for diabetic car-
diac complications using TLR4 siRNA.
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